Pneumococcal vaccine conjugate 15 valent - Merck

Drug Profile

Pneumococcal vaccine conjugate 15 valent - Merck

Alternative Names: MK-V114; Pneumococcal 15 valent vaccine conjugate - Merck; V 114; V114 aluminum-adjuvanted

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck & Co
  • Class Pneumococcal vaccines; Polysaccharides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pneumococcal infections

Most Recent Events

  • 21 Mar 2017 Phase-II clinical trials in Pneumococcal infections (Prevention, In infants) in Spain (IM) (EudraCT2016-001117-25)
  • 21 Mar 2017 Merck Sharp & Dohme initiates enrolment in a phase II trial for Pneumococcal infections (In infants, Prevention) in USA (IM) (NCT02987972)
  • 06 Dec 2016 Merck Sharp & Dohme plans a phase II trial for Pneumococcal infections (In infants, Prevention) in USA (IM) (NCT02987972)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top